Taysha Gene Therapies, Inc.
NMS: TSHALive Quote
📈 ZcoreAI Score
Our AI model analyzes Taysha Gene Therapies, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get TSHA Z-Score →About Taysha Gene Therapies, Inc.
Healthcare
Biotechnology
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
📊 Fundamental Analysis
Taysha Gene Therapies, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 171.3% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -68.5%, which indicates that capital utilization is currently under pressure.
At a current price of $4.49, TSHA currently sits at the 69th percentile of its 52-week range (Range: $1.13 - $6.02).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$1.29B
Trailing P/E
--
Forward P/E
-11.02
Beta (5Y)
1.08
52W High
$6.02
52W Low
$1.13
Avg Volume
2.64M
Day High
Day Low